An observational study in Impetigo, sponsored by GlaxoSmithKline. Completed. Per ClinicalTrials.gov, last updated 2013-06-10.
Sponsored by GlaxoSmithKline · Observational
Retapamulin, a topical pleuromutilin antibiotic, is the first in a new class of topical antibiotics approved for human use. In the European Union (EU), retapamulin is approved for the treatment of impetigo and secondarily-infected traumatic lesions in persons nine or more months of age. This study is designed to examine retapamulin use in the pediatric population less than nine months of age. We will conduct a five-year assessment of prescriptions for retapamulin using the General Practice Research Database. For each year of reporting, the observed frequencies of prescriptions of retapamulin, with or without same-day co-prescriptions of topical mupirocin or fusidic acid, will be identified. The five-year reporting period will include five years of distinct, non-overlapping, non-cumulative prescription use of first exposure to retapamulin, with or without same-day co-prescription of topical mupirocin or fusidic acid.
27 studies on the registry are indexed under Impetigo; 3 are open to participants now.
Browse Impetigo studies →GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 120 are open to participants now.
Of its 264 completed or terminated interventional studies of FDA-regulated products, 240 (91%) have results posted.
Counted across the registry records on this site, refreshed daily.
The GPRD contains detailed information for a sample of patients from representative general practices throughout the United Kingdom. Patient data included in the GPRD were drawn from the computer systems used by general practitioners to maintain the clinical records within their practices and contain all records deemed relevant to patient care. Prescriptions of Altabax, Altargo, Mupirocin and Fucidin will be captured.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Age at time of prescription was \<9 months
Drug: Retapamulin · Drug: Co-prescription of retapamulin and topical mupirocin · Drug: Co-prescription of retapamulin and topical fusidic acid
Age at time of prescription was 9 months to 6 years
Drug: Retapamulin · Drug: Co-prescription of retapamulin and topical mupirocin · Drug: Co-prescription of retapamulin and topical fusidic acid
Age at time of prescription was 7 years to 18 years
Drug: Retapamulin · Drug: Co-prescription of retapamulin and topical mupirocin · Drug: Co-prescription of retapamulin and topical fusidic acid
Age at time of prescription was 19 to 65 years
Drug: Retapamulin · Drug: Co-prescription of retapamulin and topical mupirocin · Drug: Co-prescription of retapamulin and topical fusidic acid
Age at time of prescription was 66 years and older
Drug: Retapamulin · Drug: Co-prescription of retapamulin and topical mupirocin · Drug: Co-prescription of retapamulin and topical fusidic acid
Prescription for retapamulin
Same day prescriptions for retapamulin and topical mupirocin
Same day prescription for retapamulin and fusidic acid.
Prescription for retapamulin
Time frame: First prescription in database for each calendar year between January 2007 and December 2011
Co-prescription of retapamulin and topical mupirocin
Time frame: First same-day prescriptions for both medicines in database for each calendar year between January 2007 and December 2011
Co-prescription of retapamulin and topical fusidic acid
Time frame: First same-day prescriptons for both medicines in database for each calendar year between January 2007 and December 2011
No study locations are listed for this record.
The record gives a start of Nov 2008, a primary completion of Aug 2012 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.